Taysha Gene Therapies Inc (NASDAQ:TSHA) currently has a daily average trading volume of 2.65M but it saw 10296823 shares traded in last market. With a market cap of 465.22M USD, the company’s current market price of $2.27 came rising about 2.71 while comparing to the previous closing price of $2.21. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.32 and as low as $1.19. In the recent trading on the day, stock has struck highest price mark of $1.96 while lowest mark touched by it was $2.62.
Taking a look at 20-day trading activity of Taysha Gene Therapies Inc (TSHA) gives us an average price of $1.82, while its current price level is -47.45% below from 52-week high level whereas it is 90.76% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.98 while that of 200 days or SMA-200 reads an average of $2.40. A closer look into the stock’s movement over the week reveals that its volatility is standing at 18.08% during that period while stretching the period over a month that decreases to 10.08%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 62.77 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the BMO Capital Markets which initiated the stock as “Outperform” in its note to investors issued on June 27, 2024, recommending a price target of $5 for it. Jefferies issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $14 and $1.50.
Over the week, TSHA’s stock price is moving 59.86% up while it is 11.82% when we observe its performance for the past one month. Year-to-date it is 28.25% up and over the past year, the stock is showing an upside performance of 70.68%.
Currently, Taysha Gene Therapies Inc’s total number of outstanding shares is 186.96M. Company’s return on investment (ROI) stands at -15.23% and return on equity (ROE) at -114.77%. Stock’s beta reads 0.50. Stock has a price to book (P/B) ratio of 5.24 while price to sale or P/S ratio amounts to 46.94. Its return on asset (ROA) is -12.11% on average.
